[EFFECT] ADC Therapeutics SA SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

07/10/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 9, 2025 4:00 P.M.

Form:

S-3

CIK:	0001771910
Company Name:	ADC Therapeutics SA
File Number:	333-288437

Source: View Original Filing on SEC EDGAR

Adc Therapeutics Sa

NYSE:ADCT

ADCT Rankings

#5870 Ranked by Market Cap

N/A Ranked by Dividends

ADCT Latest News

Jul 1, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jun 16, 2025

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 12, 2025

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

Jun 2, 2025

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADCT Latest SEC Filings

Jul 10, 2025

[424B3] ADC Therapeutics SA Prospectus Filed Pursuant to Rule 424(b)(3)

Jun 30, 2025

[S-3] ADC Therapeutics SA Shelf Registration Statement

ADCT Stock Data

Market Cap 282.80M

Float 71.77M

Insiders Ownership 20.64%

Institutions Ownership 63.17%

Short Percent 5.48%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country Switzerland

City EPALINGES